Immunotherapy-Related Colitis: A ‘Hot Topic’
Patients who develop immunotherapy-related colitis tend to have better outcomes, so it is important to get them back on treatment as soon as possible.
Related Articles
The Changing Landscape of Clinical Trials in Cancer Care
Although excitement surrounds the constantly changing landscape of cancer care, we have much to learn to keep our practices current.
AE Profile of Bispecific Antibodies Can Be Predictable in Myeloma Management
Both community and academic nurses must know what to expect and how to react to adverse events from bispecific antibody treatment in myeloma; however, Donna…
Oncology Nurses, APPs Play a ‘Unique Role’ in Sarcoma Treatment
An expert explained the role oncology nurses and advanced practice providers play in caring for patients with sarcoma during treatment.
Adding Nivolumab to Standard Radiotherapy Better Biochemical Recurrence Outcomes in Prostate Cancer
The addition of nivolumab to radiotherapy significantly improved freedom from biochemical recurrence in patients with high-grade prostate cancer.
Allogeneic CAR T-Cell Therapy Is Safe, Effective in Heavily Pretreated Myeloma
P-BCMA-ALLO1 elicited high response rates and a manageable safety profile in heavily pretreated, relapsed/refractory multiple myeloma.
Radium-223 Plus Enzalutamide Boosts Survival in mCRPC
The addition of radium-223 to enzalutamide led to significant rPFS and OS benefits compared to enzalutamide alone in metastatic castration-resistant prostate cancer.
Acalabrutinib Gets Priority Review for Frontline MCL Treatment
The FDA granted a priority review to acalabrutinib for the treatment of previously untreated adults with mantle cell lymphoma.
Cilta-Cel Continues to Boosts Survival in Pretreated Myeloma
Follow-up from the CARTITUDE-4 trial showed that cilta-cel improved survival over standard of care in pretreated myeloma.
Nurses, Talk AEs, Interstitial Lung Disease, Before Treating With T-DXd
Oncology nurses should inform patients about adverse events and the signs of interstitial lung disease before treating their breast cancer with T-DXd.
Dato-DXd Seems Safe, Efficacious in Advanced Gynecologic Cancers
Datopotamab deruxtecan(Dato-DXd) demonstrated antitumor activity in patients with advanced/metastatic ovarian or endometrial cancer who had prior chemotherapy treatment.